Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia
about
Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia.Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemiaSTAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 studyLarge granular lymphocytic leukaemia pathogenesis and management.Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemia.Targeted molecular therapy in peripheral T-cell lymphomas.Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab).Moderate-dose cyclophosphamide in the treatment of relapsed/refractory T-cell large granular lymphocytic leukemia-associated pure red cell aplasia.Targeting IL-15 in large granular lymphocyte leukemia.Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation.Cyclophosphamide as a first-line therapy in LGL leukemia.Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.Large granular lymphocyte leukemia: natural history and response to treatment.Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia.
P2860
Q35193715-332E8698-8D58-4D0A-B282-0145586F0F22Q35485805-A5534B31-F669-4CF7-BB31-01AE6063304DQ36318148-0EBA20ED-A3AB-47BC-A0BE-17939DD71EFCQ36486302-F54977F0-67C7-4608-BF98-7E5677BC1B14Q37821049-23912690-6799-4FCB-8ABB-C4DD9CB5A5B4Q37888717-AE402461-AB9D-4708-862D-E1C13F317048Q37937044-42EFBECC-023A-46F8-8077-3095620212A9Q38065877-68307CED-37E6-4DD1-BBC9-EEE0C9D1B028Q39851542-FD1603BA-B7BB-425A-A7E8-D73B7B5E42BEQ41866999-112A791A-4005-4CBE-BCA4-EF64E5CF2AD9Q42030698-29719B0D-5E9A-4B2B-8D9A-D61BF6B93EEFQ42563534-48CF9851-D895-459F-9947-DFDE27C474FCQ42574009-FFC978CC-07E8-4845-B545-542CE606D7CFQ43109504-228161F1-98D1-46EA-B667-B18B050B1AB3Q48349106-BEC8DEFC-5D49-4B9C-992D-6A31FD06CE0BQ55041058-1FBFBD6B-E8C7-41FE-938C-12C757BA31B6
P2860
Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Therapeutic implications of va ...... e granular lymphocyte leukemia
@ast
Therapeutic implications of va ...... e granular lymphocyte leukemia
@en
Therapeutic implications of va ...... e granular lymphocyte leukemia
@nl
type
label
Therapeutic implications of va ...... e granular lymphocyte leukemia
@ast
Therapeutic implications of va ...... e granular lymphocyte leukemia
@en
Therapeutic implications of va ...... e granular lymphocyte leukemia
@nl
prefLabel
Therapeutic implications of va ...... e granular lymphocyte leukemia
@ast
Therapeutic implications of va ...... e granular lymphocyte leukemia
@en
Therapeutic implications of va ...... e granular lymphocyte leukemia
@nl
P2093
P2860
P1433
P1476
Therapeutic implications of va ...... e granular lymphocyte leukemia
@en
P2093
Alan E Lichtin
Heather N Cazzolli
Jaroslaw P Maciejewski
Manuel Afable
Marcin W Wlodarski
Michael J Clemente
Nelli Bejanyan
Sanjay R Mohan
P2860
P304
P356
10.3324/HAEMATOL.2009.009191
P577
2009-10-01T00:00:00Z